Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial.
Dodaran MS, Banihashemi SR, Es-Haghi A, Mehrabadi MHF, Nofeli M, Mokarram AR, Mokhberalsafa L, Sadeghi F, Ranjbar A, Ansarifar A, Mohazzab A, Setarehdan SA, Bagheri Amiri F, Mohseni V, Hajimoradi M, Ghahremanzadeh N, Razzaz SH, Masoomi S, Taghdiri M, Bagheri M, Lofti M, Khorasani A, Ghader M, Safari S, Shahsavn M, Kalantari S.
Dodaran MS, et al. Among authors: ranjbar a.
Vaccines (Basel). 2023 Feb 16;11(2):455. doi: 10.3390/vaccines11020455.
Vaccines (Basel). 2023.
PMID: 36851334
Free PMC article.